Table 1.

The information of ten studies detecting VEGF level in serum.

Ref/First Author	Ethnic	No. of cases	Character	Method (kits)	Kit's Sensitivity	Biomarkers	Detecting time	Stage/ type	Treatment/ diagnosis
71 A.M. C. Dingemans	Dutch	223	Multicenter Random, protective	ELISA(R&D Systems Minneapolis, MN)	Standard curve 15-2000pg/ml	VEGF	0, 3w, 6w, PD	IV/ NSCLC	Chemotherapy
66 Andrea Camerini	Italian	43	protective	ELISA (-)	-	VEGF, TSP1	0,3w,6w,9w,3m, PD	IIIB-IV /NSCLC	Chemotherapy
73 Faruk Tas	Turk	40	protective	ELISA(R&D Systems Minneapolis, MN)	Reader at 450nm (China)	VEGF, TSP1, VEGFR-1	0,1w,2w,3w	III-IV /NSCLC	Chemotherapy
72 Martin J. Edelman	White85% black11% other3%	140	Protective Random	ELISA(R&D Systems Minneapolis, MN)	Lower Limited detection 9.0pg/ml	VEGF, COX-2 5-LOX	0, 1cycle, 2cycle	IIIB-IV /NSCLC	Chemotherapy
68 Petri SALVEN	Finnish	68	Protective Random	ELISA(R&D Systems Minneapolis, MN)	Microtitre plate reader at 450nm (50-1000pg/ml)	VEGF	0(pretreatment)	Limited- extensive /SCLC	Chemotherapy
76 Peng Zhao	Chinese	50	Protective nonrandom	ELISA(R&D Systems Minneapolis, MN)	Microplate reader at 450nm	IL-4, IL-10, IFN-γ	0, after treatment	I-III/ NSCLC	Immunotherapy
67 Junbao Liu,	Chinese	60	Protective Random	American GB company (San Francisco)	--	VEGF, bFGF, TNF-α	0, after 2m	IIIB-IV /NSCLC	Traditional Chinese medicine
74 Eleftherios Dalaveris	Greek	30	Protective	ELISA(R&D Systems Minneapolis, MN)	Lower Limited detection 0.9pg/ml	VEGF, TNF-α, 8-ISO	0(pretreatment)	IIIB-IV /NSCLC	Diagnose
70 Masaya Tamura,	Japanese	78	Protective	ELISA(R&D Systems Minneapolis, MN)	Lower Limited detection 9.0pg/ml	VEGF, VEGF-C, MMP-9	0(pretreatment)	I-III / NSCLC	Diagnose
98 Songwen Zhou	Chinese	112	Protective	ELISA(R&D Systems Minneapolis, MN, USA)	Microplate reader	VEGF, TGF-α	0, 1m	IIIB-IV /NSCLC	Targeted therapy